Living Cell Technologies Ltd. (AU:1AI) has released an update.
Algorae Pharmaceuticals has successfully launched its AI platform, AlgoraeOS, which uses advanced neural networks to predict drug target synergies. In preclinical studies, their AI-116 drug candidate for dementia showed promising results, surpassing existing treatments. The company is also advancing trials for AI-168, targeting cardiovascular diseases, with results expected soon.
For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
